Medscape is available in 5 Language Editions – Choose your Edition here.


Constipation Clinical Presentation

  • Author: Marc D Basson, MD, PhD, MBA, FACS; Chief Editor: BS Anand, MD  more...
Updated: Sep 29, 2015


Basing the diagnosis of constipation on simply asking the patients whether they are constipated is associated with marked underreporting of the problem in patients who have physical evidence of constipation, such as the presence of hemorrhoidal disease.[10] Accordingly, a careful history must be obtained, including inquiries into current medications (including over-the-counter, herbal agents, and prescription medications), previous colonoscopy, and any other medical problems present.

A constipated patient may be otherwise totally asymptomatic or may complain of one or more of the following:

  • Abdominal bloating
  • Pain on defecation
  • Rectal bleeding
  • Spurious diarrhea
  • Low back pain

The following also suggest that the patient may have difficult rectal evacuation:

  • Feeling of incomplete evacuation
  • Digital extraction
  • Tenesmus
  • Enema retention

The following signs and symptoms, if present, are grounds for particular concern:

  • Rectal bleeding
  • Abdominal pain (suggestive of possible irritable bowel syndrome [IBS] with constipation [IBS-C])
  • Inability to pass flatus
  • Vomiting
  • Unexplained weight loss

The history should begin with a detailed inquiry into the patient’s normal pattern of defecation, the frequency with which the current problem differs from the normal pattern (eg, “missing a day”), the perceived hardness of the stools, whether the patient strains in order to defecate, and any other symptoms the patient may be experiencing.

An inquiry concerning the amount of time spent on the toilet while waiting to defecate may also be illuminating. Patients should be asked to describe in detail what happens when they try to defecate and what maneuvers (pharmacologic or physical) they have used to facilitate this process. The answers to these questions may suggest chronic laxative abuse or less common causes, such as colonic outlet obstruction.

The duration of the problem is important. In adolescents or young adults, the duration of the problem may differentiate congenital defects from acquired causes. Neoplastic obstruction is less likely in younger patients or in patients older than 50 years who have had symptoms for at least 2 years and/or have recently had a screening colonoscopy. However, colon cancer certainly occurs in younger adults and even rarely in teenagers, while a previous screening colonoscopy may have missed a neoplasm.

The onset of symptoms is also very important, in that intestinal obstruction can present as acute constipation. In the hospital setting, ileus from another illness or Ogilvie syndrome should also be considered. Questions regarding the onset of constipation may provide useful etiologic information, whether in terms of changes in diet, new medications, or associated psychosocial difficulties at that time.

In addition to defining the nature of the patient’s bowel habit, it is necessary to try to identify the factors likely to be responsible for the abnormal bowel habit. Most patients who are constipated consume either too little fiber or too little water; therefore, assessing the patient’s diet is useful. For acute changes in the bowel habit, a parallel dietary change should be ascertained.

Learning how much fluid and what types of fluids the patient drinks on an average day is important. Epidemiologic studies have clearly established a link between coffee consumption and worsening constipation. The diuretic effects of coffee, tea, and alcohol are likely counterproductive. Milk products may cause constipation in some individuals.

The state of patients’ bowel motility represents a balance between factors that promote motility and factors that inhibit it. The most important influencing factor is exercise, which stimulates bowel motility. Conversely, narcotics, antipsychotic agents, and other constipating medications reduce motility. Diuretics or substantial amounts of coffee, tea, or alcohol decrease available water in the colon. Chronic laxative abuse also causes refractory constipation.

If the patient shows evidence of diseases or symptoms associated with constipation, such as diverticular disease, hemorrhoids, anal fissures, or fistula in ano, delineating these conditions historically and determining the nature of any previous therapy for them is appropriate. For instance, patients with hemorrhoids may neglect to mention that they were previously treated for this problem or that they have been receiving medications for constipation for several years.

Rectal bleeding should be taken seriously and evaluated carefully, particularly in patients who are older than 50 years or have a family history of colorectal disease. Patients with hemorrhoids may also have rectosigmoid cancer. Both cancer and hemorrhoids can produce bright red blood from the rectum. Most patients older than 50 years or with a family history of colorectal disease should be screened for colorectal cancer. A full colonoscopy is preferable, although in some cases flexible sigmoidoscopy or barium enema may be used if colonoscopy cannot be performed. The role of computed tomography (CT) colography in this setting awaits definition, although it offers an attractive alternative in the patient in whom colonoscopy is attempted and fails.

Finally, the evaluation should include the patient’s description of the act of defecation. Pain during defecation might suggest a fissure or tenesmus from a rectal tumor. Painless inability to pass an otherwise soft stool suggests a rectal outlet obstruction.

Neurologic and endocrine disorders also can cause constipation. Most notably, diabetes may be associated with chronic dysmotility. Patients with hypothyroidism may exhibit decreased motility and slow transit times.[11] Patients with panhypopituitarism, pheochromocytoma, or multiple endocrine neoplasia 2B are also at risk for constipation. When no other cause can be determined, a careful endocrine review is particularly important for patients with a recent onset of constipation and for patients who are refractory to conservative treatment.

Similarly, central nervous system (CNS) diseases, such as Parkinson disease, multiple sclerosis, stroke, CNS syphilis, and spinal injury or tumors, may cause constipation and should be considered in the patient’s history and evaluation.

Some cases of constipation may have a psychogenic component. On one hand, constipation is a frequent somatic expression of psychological distress; on the other, constipation itself may give rise to psychological disturbances.

A history of sexual abuse is observed with unusual frequency in patients who are chronically constipated, particularly those with anismus. A history of other psychological abnormalities is often found, particularly among patients who are refractory to medical treatment and have normal bowel transit times and normal results from anorectal studies.

Such factors should be gently explored in patients in whom first-line conservative treatment has failed. Psychiatric referral may be appropriate in such patients when medical evaluation and therapy have been exhausted or when gentle questioning reveals some unexpected information.


Physical Examination

General physical examination often is of no benefit in determining the etiology or in deciding the treatment. In addition to the general evaluation, the abdomen, pelvis, and rectum, specifically, should be physically examined. Both the cause of constipation and its effects should be sought.[10]

Abdominal distention or masses may indicate the presence of colonic stools or tumors. Large abdominal wall hernias, especially ventral hernias, may interfere with generation of the intra-abdominal pressure required for the initiation of defecation. Rarely, a left-sided sliding inguinal hernia with an incarcerated sigmoid colon may cause difficulties in bowel movements.

It was once widely held that elderly patients with new inguinal hernias should be assumed to have occult constipation due to partially obstructing colonic neoplasms and that these patients therefore required colorectal cancer screening. At present, the requirement for colorectal cancer screening in such patients remains controversial. The pathophysiology underlying a link between colonic neoplasms and hernias is unknown, because the lesions detected on screening are early lesions and are unlikely to have caused constipation.

Pelvic examination in women should specifically address the posterior vaginal wall, with particular attention to any evidence of internal prolapse or rectocele. This region should be palpated while the patient is at rest and then while she is straining to defecate. Many women with rectocele do not experience constipation. Good surgical results are not guaranteed, and a thorough preoperative workup to rule out other potential causes of constipation should always be performed.

During the anorectal examination, the patient should be assessed for the following:

  • Perianal excoriation
  • Skin tags/ hemorrhoids
  • Anal fissure
  • Anocutaneous reflex
  • Prolapse during straining
  • Stool amount and consistency - More stool is present within the rectal vault in pelvic outlet dysfunction than in colonic inertia or IBS, in which little or no stool remains in the rectum between defecations; pelvic floor dysfunction is manifested by failure of descent of the examining finger and contraction of the upper segment of the sphincter during straining

Digital rectal examination provides information about the following:

  • Anorectal masses
  • Tone of the internal anal sphincter
  • Strength of the external anal sphincter and puborectalis muscle
  • Presence of a rectocele (an outpouching usually present in the anterior rectal wall)
  • Presence of gross blood or occult bleeding by checking the stool guaiac
  • Presence of fecal impaction

The anorectal examination should attempt to ascertain the cause of the constipation. Causes that may be defined include the following:

  • Anal fissure, particularly in children who retain their feces in order to avoid painful defecation
  • Anal stenosis
  • Partially obstructing rectal masses

Rectal prolapse may be either external or internal. The anus should be carefully examined for prolapse at rest and during a Valsalva maneuver. Care should be taken to distinguish a true full-thickness rectal prolapse from a mucosal prolapse, which is unlikely to cause constipation. Asking the patient to perform a Valsalva with the examining finger in the rectum in order to seek evidence of an internal prolapse may be worthwhile, although this is a relatively insensitive way of diagnosing prolapse.

In contrast to inguinal hernias, rectal prolapse is typically related to constipation. At least 1 retrospective study has demonstrated a strong association between rectal prolapse and rectosigmoid neoplasms in patients older than 50 years. Sigmoidoscopy is probably indicated for these patients, and full colonoscopy should be performed if they are otherwise due for colorectal cancer screening.

In addition to delineating the cause of the constipation, the anorectal examination should be used to determine the effects of the constipation. The presence of fissures or fistulae, any evidence of scars from previous perirectal abscess drainages or other surgeries, and the nature of the patient’s hemorrhoidal columns should be noted and characterized. Enlarged hemorrhoids do not require treatment unless they cause symptoms.

Although the effectiveness of fecal occult blood testing has been hotly debated, performing such a test after a rectal examination in patients older than 50 years is probably worthwhile. The presence of blood in the stool warrants further evaluation. Never assume that the patient is bleeding from hemorrhoids or fissures until other sources of bleeding have been ruled out.

A complete physical evaluation of the patient should also include a search for the evidence of systemic diseases that may be contributing to constipation. Such systemic diseases include the following:

  • Endocrine dysfunctions (eg, hypothyroidism, hypopituitarism, and diabetes mellitus)
  • Neurologic abnormalities (eg, brain or spinal cord injury, peripheral neuropathy, multiple sclerosis, and Parkinson disease)
Contributor Information and Disclosures

Marc D Basson, MD, PhD, MBA, FACS Associate Dean for Medicine, Professor of Surgery and Basic Science, University of North Dakota School of Medicine and Health Sciences

Marc D Basson, MD, PhD, MBA, FACS is a member of the following medical societies: Alpha Omega Alpha, American College of Surgeons, American Gastroenterological Association, Phi Beta Kappa, Sigma Xi

Disclosure: Nothing to disclose.

Chief Editor

BS Anand, MD Professor, Department of Internal Medicine, Division of Gastroenterology, Baylor College of Medicine

BS Anand, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.


BS Anand, MD Professor, Department of Internal Medicine, Division of Gastroenterology, Baylor College of Medicine

BS Anand, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association, and American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Barry E Brenner, MD, PhD, FACEP Professor of Emergency Medicine, Professor of Internal Medicine, Program Director, Emergency Medicine, University Hospitals, Case Medical Center

Barry E Brenner, MD, PhD, FACEP is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Chest Physicians, American College of Emergency Physicians, American College of Physicians, American Heart Association, American Thoracic Society, Arkansas Medical Society, New York Academy of Medicine, New York Academy ofSciences, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

William K Chiang, MD Associate Professor, Department of Emergency Medicine, New York University School of Medicine; Chief of Service, Department of Emergency Medicine, Bellevue Hospital Center

William K Chiang, MD is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Medical Toxicology, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Ronnie Fass, MD, FACP, FACG Chief of Gastroenterology, Head of Neuroenteric Clinical Research Group, Southern Arizona Veterans Affairs Health Care System; Professor of Medicine, Division of Gastroenterology, University of Arizona School of Medicine

Ronnie Fass, MD, FACP, FACG is a member of the following medical societies: American College of Gastroenterology, American College of Physicians-American Society of Internal Medicine, American Gastroenterological Association, American Motility Society, American Society for Gastrointestinal Endoscopy, and Israel Medical Association

Disclosure: Takeda Pharmaceuticals Grant/research funds Conducting research; Takeda Pharmaceuticals Consulting fee Consulting; Takeda Pharmaceuticals Honoraria Speaking and teaching; Vecta Consulting fee Consulting; XenoPort Consulting fee Consulting; Eisai Honoraria Speaking and teaching; Wyeth Pharmaceuticals Conducting research; AstraZeneca Grant/research funds Conducting research; Eisai Consulting fee Consulting

Eugene Hardin, MD, FAAEM, FACEP Former Chair and Associate Professor, Department of Emergency Medicine, Charles Drew University of Medicine and Science; Former Chair, Department of Emergency Medicine, Martin Luther King Jr/Drew Medical Center

Disclosure: Nothing to disclose.

Dave A Holson, MD, MBBS, MPH Assistant Professor of Emergency Medicine, Mount Sinai School of Medicine; Director, Department of Emergency Medicine, Queens Hospital Center

Dave A Holson, MD, MBBS, MPH is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, National Medical Association, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

  1. Pharmaceutical Business Review. Ironwood Pharma, Forest Labs Present Linaclotide Phase 3 Trial Results. Available at Accessed: May 4, 2010.

  2. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006 Apr. 130(5):1480-91. [Medline].

  3. Uher R, Farmer A, Henigsberg N, et al. Adverse reactions to antidepressants. Br J Psychiatry. 2009 Sep. 195(3):202-10. [Medline].

  4. Staats PS, Markowitz J, Schein J. Incidence of constipation associated with long-acting opioid therapy: a comparative study. South Med J. 2004 Feb. 97(2):129-34. [Medline].

  5. Martin BC, Barghout V, Cerulli A. Direct medical costs of constipation in the United States. Manag Care Interface. 2006 Dec. 19(12):43-9. [Medline].

  6. Peppas G, Alexiou VG, Mourtzoukou E, et al. Epidemiology of constipation in Europe and Oceania: a systematic review. BMC Gastroenterol. 2008 Feb 12. 8:5. [Medline].

  7. Sonnenberg A, Koch TR. Epidemiology of constipation in the United States. Dis Colon Rectum. 1989 Jan. 32(1):1-8. [Medline].

  8. Bouras EP, Tangalos EG. Chronic constipation in the elderly. Gastroenterol Clin North Am. 2009 Sep. 38(3):463-80. [Medline].

  9. Amselem C, Puigdollers A, Azpiroz F, et al. Constipation: a potential cause of pelvic floor damage?. Neurogastroenterol Motil. 2010 Feb. 22(2):150-3, e48. [Medline].

  10. Noguera A, Centeno C, Librada S, Nabal M. Screening for constipation in palliative care patients. J Palliat Med. 2009 Oct. 12(10):915-20. [Medline].

  11. Taghavi SA, Shabani S, Mehramiri A, et al. Colchicine is effective for short-term treatment of slow transit constipation: a double-blind placebo-controlled clinical trial. Int J Colorectal Dis. 2010 Mar. 25(3):389-94. [Medline].

  12. Gladman MA, Knowles CH. Novel concepts in the diagnosis, pathophysiology and management of idiopathic megabowel. Colorectal Dis. 2008 Jul. 10(6):531-8; discussion 538-40. [Medline].

  13. Brooks M. FDA Issues Safety Warning for Sodium Phosphate for Constipation. Medscape [serial online]. Available at Accessed: January 13, 2014.

  14. FDA Safety Announcement. FDA warns of possible harm from exceeding recommended dose of over-the-counter sodium phosphate products to treat constipation. US Food and Drug Administration. Available at Accessed: January 13, 2014.

  15. Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut. 2011 Feb. 60(2):209-18. [Medline].

  16. Melville NA. Long-Term Efficacy With Lubiprostone in Opioid Constipation. Medscape [serial online]. Available at Accessed: September 16, 2013.

  17. Lembo AJ, Kurtz CB, Macdougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology. 2010 Mar. 138(3):886-95.e1. [Medline].

  18. Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med. 2011 Aug 11. 365(6):527-36. [Medline]. [Full Text].

  19. Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012 Nov. 107(11):1714-24; quiz p.1725. [Medline].

  20. Brown SR. Tegaserod for chronic constipation. J Fam Pract. 2005 Dec. 54(12):1060, 1063. [Medline].

  21. Di Palma JA. Expert commentary--new developments in the treatment of constipation. MedGenMed. 2005 Jan 1. 7(1):17. [Medline].

  22. Layer P, Keller J, Loeffler H, et al. Tegaserod in the treatment of irritable bowel syndrome (IBS) with constipation as the prime symptom. Ther Clin Risk Manag. 2007 Mar. 3(1):107-18. [Medline].

  23. Zelnorm (tegaserod) emergency treatment IND program. Novartis Pharmaceuticals Corp. July 16, 2014.

  24. Johanson JF. Review of the treatment options for chronic constipation. MedGenMed [serial online]. May 2, 2007;9 (2):25-40. Available at Accessed: April 26, 2010.

  25. Hsiao KC, Jao SW, Wu CC, et al. Hand-assisted laparoscopic total colectomy for slow transit constipation. Int J Colorectal Dis. 2008 Apr. 23(4):419-24. [Medline].

  26. Tomita R, Fujisak S. Minilaparotomy with a gasless laparoscopic-assisted procedure by abdominal wall lifting for ileorectal anastomosis in patients with slow transit constipation. Hepatogastroenterology. 2009 Jul-Aug. 56(93):1022-7. [Medline].

  27. Frascio M, Stabilini C, Ricci B, et al. Stapled transanal rectal resection for outlet obstruction syndrome: results and follow-up. World J Surg. 2008 Jun. 32(6):1110-5. [Medline].

  28. Bona S, Battafarano F, Fumagalli Romario U, et al. Stapled anopexy: postoperative course and functional outcome in 400 patients. Dis Colon Rectum. 2008 Jun. 51(6):950-5. [Medline].

  29. van den Esschert JW, van Geloven AA, Vermulst N, Groenedijk AG, de Wit LT, Gerhards MF. Laparoscopic ventral rectopexy for obstructed defecation syndrome. Surg Endosc. 2008 Dec. 22(12):2728-32. [Medline].

  30. Mowatt G, Glazener C, Jarrett M. Sacral nerve stimulation for fecal incontinence and constipation in adults: a short version Cochrane review. Neurourol Urodyn. 2008. 27(3):155-61. [Medline].

  31. Holzer B, Rosen HR, Novi G, et al. Sacral nerve stimulation in patients with severe constipation. Dis Colon Rectum. 2008 May. 51(5):524-29; discussion 529-30. [Medline].

  32. Biggs WS, Dery WH. Evaluation and treatment of constipation in infants and children. Am Fam Physician. 2006 Feb 1. 73(3):469-77. [Medline].

  33. Cryer B, Katz S, Vallejo R, Popescu A, Ueno R. A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain. Pain Med. 2014 Nov. 15(11):1825-34. [Medline].

  34. Jeffrey S. FDA Approves Amitiza for Opioid-Induced Constipation. Medscape Medical News. April 23, 2013. Available at Accessed: April 30, 2013.

  35. Anderson P. FDA okays naloxegol (Movantik) in opioid-induced constipation. Medscape Medical News. September 16, 2014. [Full Text].

  36. Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014 Jun 19. 370(25):2387-96. [Medline].

  37. Webster L, Chey WD, Tack J, Lappalainen J, Diva U, Sostek M. Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation. Aliment Pharmacol Ther. 2014 Oct. 40(7):771-9. [Medline].

  38. Relistor (methylnaltrexone bromide) subcutaneous injection [package insert]. Tarrytown, NY: Progenics Pharmaceuticals, Inc. September, 2014. Available at [Full Text].

  39. Camilleri M, Beyens G, Kerstens R, Robinson P, Vandeplassche L. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil. 2009 Dec. 21(12):1256-e117. [Medline].

  40. US Food and Drug Administration. FDA approves Movantik for opioid-induced constipation. 2014 Sept 16. Available at Accessed: September 16, 2014.

Large amount of stool throughout colon.
Large stool mass in hepatic flexure of colon.
Colon distention secondary to fecal impaction.
Pseudo-obstruction secondary to fecal impaction.
Distended transverse colon.
Distended rectum.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.